Navigation Links
?EastGate Acquisitions Augments Its Sub-Micron Self-Nanoemulsifying Platform Technology
Date:8/18/2014

SALT LAKE CITY and TORONTO, Aug. 18 , 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options. The various technologies are applicable to the company's current pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company recently expanded its new product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.

The company's technology platform led to the development of several improved novel formulations and alternative dosage forms for delivery of known biologically active molecules. The technology utilizes EastGate's sub-micron self-emulsifying delivery vehicle and facilitates the creation of harmonized formulations with better drug absorption. The company's technological approaches have demonstrated robustness and resulted in diversification of the drug delivery products. The variety of developed dosage forms includes liquid spray or droplets, semi-solid, compressed tablets and capsules of different types.

The purpose of offering this spectrum of dosage forms is to provide patients with different treatment possibilities and bring products that will fit their lifestyle and improve patient's compliance.

Currently the company is working towards acquiring the licensing rights to develop and manufacture an intraoral insulin formulation. The intraoral insulin dosage forms under consideration are liquid and solid dosage forms, such as compressed tablet which can be deli vered to the mouth for intraoral absorption. 

"We have recognized the importance of expanding our sub-micron self-nanoemulsifying platform technology to include different dosage forms and delivery methods," says Anna Gluskin, EastGate's CEO. "The versatility of the sub-micron platform technology will continue to validate the company's sub-micron approach and provide a unique opportunity to offer different absorption-enhanced products to widen the target patient population," states Gluskin.

About EastGate Acquisitions Corporation

EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules. The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGa te's approach will be most beneficial for patient care. For more information, please visit the company's website at www.EastGatePharmaceuticals.com.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Rose Perri 1-647-692-0652
Email: information@eastgatepharmaceuticals.com  
Text:  ESAQ to 87804


'/>"/>
SOURCE EastGate Acquisitions Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
2. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
3. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
4. VWR International, LLC Expands European Portfolio With Acquisitions Of Labonord SAS And Switch BVBA
5. Hanger, Inc. Has Record Year In O&P Acquisitions:
6. Medbox, Inc. Commences Pursuit of Strategic Acquisitions
7. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
8. Hanger Announces 2013 Year-To-Date Acquisitions Totaling $10 Million Of Annualized Net Revenue
9. Sanomedics Receives Financing for Working Capital and Acquisitions
10. Sleep Nation, Inc. Completes 43 Acquisitions
11. Acquisitions, Conference Participations, Court Rulings, and Product Deliveries - Research Report on Zoetis, Aegerion Pharmaceuticals, Edwards, Community Health Systems, and Air Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., the ... to announce the appointment of George M. Rapier, III ... San Antonio, TX , WellMed is one of the ... patients and HMO members in Texas ... 1990 out of his own internal medicine practice, he has ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug Development: ... EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products are ... attention from all stakeholders in the development of new chemical entities. , However, ...
(Date:2/12/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... Awards 2016. Finalists and winners of the ISE® Awards for both Executive and ... Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. , ...
(Date:2/12/2016)... ... 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined ... Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System ... This will be the first Fisher House in Nevada, and will provide free ...
Breaking Medicine News(10 mins):